The short answer
Hodgkin lymphoma is most often diagnosed in young adults and most people are cured. Because of that, two things belong in the first week: a decision about fertility preservation before treatment starts, and an understanding of which of three prognostic groups you are in.
Hodgkin lymphoma is most frequently diagnosed between ages 20 and 34. SEER puts five-year relative survival at 89.3 percent, based on people diagnosed between 2016 and 2022.
Treatment is planned by three groups, not by stage alone: early favourable, early unfavourable, and advanced.
For stage III and IV disease, NCI says nivolumab with AVD has become the treatment of choice, replacing ABVD.
Sperm or egg freezing is the first choice for protecting fertility, and it has to happen before treatment begins.
Choose how you want to understand this
The full explanation.
The decision with a deadline
Hodgkin lymphoma is unusual among cancers. It is most often found in young adults, and most people are cured. For 2026 the American Cancer Society projects 8,920 new US cases and 1,100 deaths, a projection SEER carries on its Stat Facts page. NCI's SEER measurements show it is diagnosed most frequently between ages 20 and 34, give a median age of 38, and put five-year relative survival at 89.3 percent, based on people diagnosed between 2016 and 2022.
That high cure rate is exactly why fertility comes up on day one. NCI says freezing eggs or sperm remains the first choice for preserving fertility. It cannot be done once treatment has started.
The risk depends on the drugs. NCI reports that ABVD appears to spare long-term testicular and ovarian function. Regimens containing alkylating drugs are different. After six to eight cycles of BEACOPP, 82 percent of women under 30 got their periods back, but only 45 percent of women over 30 did.
If nobody has raised fertility with you, raise it yourself, and ask for a referral this week.
Three groups, not four stages
Stage matters, but NCI describes a three-group system that clinicians and trials actually use.
Early-stage disease is sorted into favourable or unfavourable by five adverse factors:
- A large mass in the chest, over a third of the chest width on x-ray or 10 cm or more on CT.
- Involvement of a site outside the lymph nodes.
- A raised erythrocyte sedimentation rate.
- Three or more lymph node areas involved.
- B symptoms, meaning fever, drenching night sweats, or weight loss.
Stage I or II with none of these is early favourable. Stage I or II with one or more is early unfavourable. Stage III or IV is the advanced group, where NCI reports a 60 to 80 percent rate of freedom from progression at five years with first-line chemotherapy.
For advanced disease there is also a seven-factor score. It counts low albumin, low haemoglobin, male sex, age 45 or over, stage IV disease, a high white cell count, and a low lymphocyte count.
What frontline treatment is now
For early-stage disease, NCI describes ABVD with or without radiation to the involved area. ABVD is doxorubicin, bleomycin, vinblastine, and dacarbazine. In one large trial, two cycles of ABVD plus 20 Gy of radiation was enough for early favourable disease.
For stage III and IV disease, the standard changed. NCI says nivolumab with AVD and brentuximab vedotin with AVD have replaced ABVD, which held that place for three decades. Both are given for six cycles. AVD is ABVD without the bleomycin.
The trial behind that ran with 994 people. Two-year progression-free survival was 92 percent with nivolumab plus AVD and 83 percent with brentuximab vedotin plus AVD. Side effects also differed sharply. Sensory nerve damage of grade 2 or worse affected 32 percent on the brentuximab arm and 3 percent on the nivolumab arm, and twice as many people stopped early. NCI states that nivolumab with AVD has become the treatment of choice for stages III and IV. It adds that ABVD remains viable where cost is a real constraint.
The FDA label for nivolumab covers previously untreated stage III or IV classical Hodgkin lymphoma, in combination with AVD, for adults and children aged 12 and over.
The scan after two cycles
You will hear about a PET-CT taken after two cycles, often shortened to PET2. NCI calls it the best predictor of treatment failure.
It is not a verdict. In limited-stage disease, positive results are often false alarms because relapse is uncommon to begin with. In advanced disease, up to 15 percent of people relapse even after a negative PET2. Scans are read on a five-point Deauville scale. NCI counts a score of 1 or 2 as negative, and a score of 3, 4 or 5 as positive.
Ask what the plan would be for each result, before the scan happens.
Late effects belong in this conversation
Because so many people live decades after Hodgkin lymphoma, the long view is part of choosing treatment now.
NCI puts the risk of acute leukaemia at 10 years after MOPP-containing regimens at about 3 percent, and under 1 percent after ABVD. In a survey of 20,007 people treated between 2000 and 2016, heart disease and infection were the leading causes of death that were not from lymphoma, especially over age 60. Bleomycin can damage the lungs, and NCI notes this is seen in people older than 40.
None of this is a reason to refuse treatment. It is a reason to ask why a particular regimen was chosen for you.
When to get help sooner
- Call 911 or go to an emergency department if your face or neck swells, veins stand out on the chest, or swallowing and breathing become difficult. A large chest mass, one of the five adverse factors above, can press on the airway and the great veins.
- Call 911 or go to an emergency department if chest pain, fainting, or a pounding irregular heartbeat occurs. Doxorubicin can affect the heart, and heart disease is a leading late cause of death after this treatment.
- Call 911 or go to an emergency department if you record 100.4°F (38°C) or higher on a thermometer, or shaking chills begin, while you are having chemotherapy. The drugs in these regimens drop your white cell count, and CDC treats a fever at that point as a medical emergency. Go straight in; do not wait to hear back from the clinic.
- Call your care team the same day if breathlessness or a dry cough starts or worsens during or after bleomycin. NCI notes lung damage from it in people over 40, and the drug is stopped rather than pushed through.
- Call your care team within a day or two if a rash spreads, diarrhoea persists, or fatigue deepens sharply while you are on nivolumab. Immune side effects respond best when caught early.
- Call your care team within a day or two if numbness, tingling, or weakness appears in your hands or feet, since nerve damage is dose-related and doses can be adjusted.
Related pages
Hodgkin vs Non-Hodgkin Lymphoma, What Is ABVD Chemotherapy?, Fertility Preservation Before Cancer Treatment, and Lymphoma Treatment by Stage and Type.
Sources
Words to know
Tap any term to see what it means.
Common questions
Should I talk about fertility before treatment?
Yes, and quickly. NCI states that freezing eggs or sperm remains the first choice for preserving fertility. ABVD appears to spare long-term ovarian and testicular function, but regimens containing alkylating drugs carry a much higher risk.
Why does a PET scan after two cycles matter so much?
NCI calls the PET-CT taken after two cycles the best predictor of treatment failure. In advanced disease, up to 15 percent of people still relapse despite a negative scan, so it guides the plan rather than settling it.
Has the standard chemotherapy changed?
For advanced disease, yes. NCI says nivolumab plus AVD and brentuximab vedotin plus AVD have replaced ABVD, which was the standard for three decades. ABVD remains a viable option where cost is a constraint.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Your next step
Turn this topic into questions for your next appointment.
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Knowledge Check
0 of 3 answered
This self-assessment checks understanding of educational content only. It is not medical advice.
Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Sources last checked: 2026-08-18 what this meansLast updated: 2026-08-18Next planned review: 2027-07-20
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source checked. This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
General education — varies by person. Answers genuinely differ between people. This page explains what commonly varies and points you to your care team for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source checked — This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
Still have questions?
Educational answers, plain language
Free to print and share